Johnson & Johnson (JNJ)
International Stocks
Buy
The speaker scrutinizes the healthcare giant's new FDA approvals and the subsequent market reaction.
Jim Cramer28d
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Analysts are largely in agreement
Last evaluation 28 days ago
One-directional consensus
Decreasing interest recently
Chronological view of analyst recommendations for this asset
The speaker scrutinizes the healthcare giant's new FDA approvals and the subsequent market reaction.
CNBC TelevisionThe speaker examines the potential sale of the company's orthopedics unit and the strategic implications of this transaction.
CNBC TelevisionThe company's solid earnings, valuation, and overall market performance are examined.
CNBC TelevisionThe anchor evaluates Morgan Stanley upgrading the stock rating to 'Overweight' and the commercial momentum.
Yahoo FinanceThe speaker evaluates the company's reported financial results, its performance in the medical technology sector, and future projections. The analysis covers management's strategic moves and the potential of new products in the pipeline.
CNBC TelevisionThe speaker analyzes the performance of the pharmaceutical sector in the current political environment and the reflection of government policies on company profitability.
CNBC TelevisionThe speaker reviews the company's new product cycle, developments in oncology, and the impact of litigation processes on the stock.
Yahoo FinanceThe analyst interprets the better-than-expected sales figures and the impact of the new drug cycle on the company's growth.
Yahoo FinanceThe speaker analyzes the company's pharma-focused structure post-restructuring and the diminishing impact of legal proceedings on the stock.
CNBC TelevisionThe speaker examines the company's new pharma-focused structure after spinning off its orthopedics division and the litigation processes.
CNBC TelevisionThe speaker evaluates the growth momentum in the company's oncology portfolio, the effects of the Kenvue spinoff, and the reduction of risks in litigation processes. He analyzes the stock's valuation and its position relative to other players in the sector.
CNBC TelevisionThe anchor reports the company reached a deal with the administration for tariff exemptions in exchange for drug price cuts, confirming a $55 billion investment plan.
CNBC TelevisionThe speaker evaluates the new agreement announced by the company and its relationship with the administration within the context of pricing policies in the sector.
CNBC TelevisionThe speaker interprets the health giant's changing valuation dynamics post-spinoff and the growth potential of its pharma business.
CNBC TelevisionThe growth potential in the core pharmaceutical business following the spin-off of the orthopedic unit and the current price level are evaluated.
CNBC TelevisionThe speaker analyzes Johnson & Johnson's dollar-based dividend growth performance and technical support points.
FİNANS VE BORSAThe speaker analyzes the company as a key player making significant moves in the neuro field and contributing to the sector's momentum.
CNBC TelevisionThe speaker analyzes the transition of money exiting tech stocks into defensive and established companies.
CNBC TelevisionThe speaker evaluates the company's business diversity in consumer products, medtech, and oncology, and the impact of this structure on the portfolio.
CNBC TelevisionThe speaker reviews Johnson & Johnson's (JNJ) stock performance, highlighting its gain of over 1%.
Yahoo FinanceThe speaker scrutinizes the healthcare giant's new FDA approvals and the subsequent market reaction.
* Does not constitute investment advice
The speaker examines the potential sale of the company's orthopedics unit and the strategic implications of this transaction.
* Does not constitute investment advice
The company's solid earnings, valuation, and overall market performance are examined.
* Does not constitute investment advice
The anchor evaluates Morgan Stanley upgrading the stock rating to 'Overweight' and the commercial momentum.
* Does not constitute investment advice
The speaker evaluates the company's reported financial results, its performance in the medical technology sector, and future projections. The analysis covers management's strategic moves and the potential of new products in the pipeline.
* Does not constitute investment advice
The speaker analyzes the performance of the pharmaceutical sector in the current political environment and the reflection of government policies on company profitability.
* Does not constitute investment advice
The speaker reviews the company's new product cycle, developments in oncology, and the impact of litigation processes on the stock.
* Does not constitute investment advice
The analyst interprets the better-than-expected sales figures and the impact of the new drug cycle on the company's growth.
* Does not constitute investment advice
The speaker analyzes the company's pharma-focused structure post-restructuring and the diminishing impact of legal proceedings on the stock.
* Does not constitute investment advice
The speaker examines the company's new pharma-focused structure after spinning off its orthopedics division and the litigation processes.
* Does not constitute investment advice
The speaker evaluates the growth momentum in the company's oncology portfolio, the effects of the Kenvue spinoff, and the reduction of risks in litigation processes. He analyzes the stock's valuation and its position relative to other players in the sector.
* Does not constitute investment advice
The anchor reports the company reached a deal with the administration for tariff exemptions in exchange for drug price cuts, confirming a $55 billion investment plan.
* Does not constitute investment advice
The speaker evaluates the new agreement announced by the company and its relationship with the administration within the context of pricing policies in the sector.
* Does not constitute investment advice
The speaker interprets the health giant's changing valuation dynamics post-spinoff and the growth potential of its pharma business.
* Does not constitute investment advice
The growth potential in the core pharmaceutical business following the spin-off of the orthopedic unit and the current price level are evaluated.
* Does not constitute investment advice
The speaker analyzes Johnson & Johnson's dollar-based dividend growth performance and technical support points.
* Does not constitute investment advice
The speaker analyzes the company as a key player making significant moves in the neuro field and contributing to the sector's momentum.
* Does not constitute investment advice
The speaker analyzes the transition of money exiting tech stocks into defensive and established companies.
* Does not constitute investment advice
The speaker evaluates the company's business diversity in consumer products, medtech, and oncology, and the impact of this structure on the portfolio.
* Does not constitute investment advice
The speaker reviews Johnson & Johnson's (JNJ) stock performance, highlighting its gain of over 1%.
* Does not constitute investment advice